Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors.

ESMO Gastrointest Oncol · 2026 · PMC13213628 · PMID 42211408

Europe PMC DOI

hedged sentence

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

showed a trendP = 0.078so close (0.05 < p ≤ 0.1)

Other predictors were nonsignificant, although age showed a trend (14.9% increase per SD, P = 0.078).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.